Please find attached the Outcome of Board meeting held on 7th August, 2026

Date: 07-08-2026 To To The General Manager The Manager Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Tower Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Mumbai - 400 051 Ref: BSE Scrip Code: 533259; NSE Symbol: HEALTHX Sub: Outcome of Board meeting held on 7th August, 2026 Dear Sir/ Madam, Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘SEBI Listing Regulations’) we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. on 7th August, 2026, inter-alia, transacted the following businesses: 1. Pursuant to Regulation 30 and 33 of the SEBI Listing Regulations, this is to inform you that the Board of Directors of the Company has approved and taken on record the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter ended 30th June, 2026 and Limited Review Report of the Statutory Auditors on the financial results. The said results have been reviewed by the Audit Committee of the Board. A copy of the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter ended 30th June, 2026 along with the Limited Review Report of the Statutory Auditors thereon is enclosed herewith. 2. Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI Listing Regulations, this is to inform you that the Board of Directors of the Company, has approved, based on the recommendations of Nomination and Remuneration Committee, the re-appointment of Mrs. Anjana Dikshit (DIN - 10377490) as an Independent Director of the Company for a second term of 5 (five) consecutive years, w.e.f. November 10, 2026 subject to the approval of the shareholders before the conclusion of first term. The Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority. Details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as Annexure A. The Meeting of the Board of Directors of the Company commenced at 3.30 P.M. and concluded at 4.25 P.M. Kindly take note of the above and acknowledge the receipt. Thanking you, Yours faithfully, For Health X Platform Limited (formerly known as Sastasundar Ventures Limited) Pratap Singh Company Secretary & Compliance Officer M. No.: A24081 Encl: As above Annexure – A Sr. Details of Event that Informa(cid:415)on(s) of such event No. needs to be provided 1. Reason for change viz. Re-appointment of Mrs. Anjana Dikshit (DIN - 10377490) as appointment, an Independent Director of the Company for the second term re-appointment, of 5 (five) consecu(cid:415)ve year w.e.f. 10th November, 2026. resigna(cid:415)on, removal, death or otherwise 2. Date of appointment/ re- Re-appointed for the second term w.e.f. 10th November, appointment/cessa(cid:415)on 2026, for a period of 5 (five) years subject to approval of and term of shareholders of the Company before the conclusion of the appointment/ re- first term. appointment 3. Brief Profile (in case of Mrs. Anjana Dikshit is an IT Professional and had appointment) superannuated from IBM India in 2022 as an Associate Director in the ERP Prac(cid:415)ce. She is presently serving in the Board of mul(cid:415)ple public limited companies. She is also into educa(cid:415)on and training in Digital Technologies for Corporates and also a visi(cid:415)ng faculty at Management Schools. In IBM, Mrs. Dikshit was responsible for large scale global ERP implementa(cid:415)ons across mul(cid:415)ple geographies. She had started her career from Tata Motors, Jamshedpur before moving to IBM. Mrs. Dikshit is a Mechanical Engineer from BIT Mesra and holds a Post Graduate Diploma in Management from XLRI Jamshedpur. 4. Disclosure of Mrs. Anjana Dikshit is not related to any of the Directors or rela(cid:415)onships between Promoters of the Company. directors (in case of appointment of a director) JKVS&CO Chartered Accountants Edcons Court, 7118, Hazra Road, 2nd Floor, Kolkata-700 026 . Phone: +91 33 2416 506g. E-mait: kotkata@ikvs.in Independent Auditor's Limited Review Report on the Quarterly Unaudited Standalone Financial Results of Health X Platform Limited fFormerly known as Sastasundar Ventures Limited) for the quarter ended tune 30,2026, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended The Board ofDirectors Health x Pladorm Limited (Formerly known as sastasundar ventures Limited) We have reviewed the accompanying statement of unaudited standalone financial results of M/s. Heralth X Platform Limited [Formerly known as Sastasundar Ventures Limited) (the'Company') for the quarter ended fune 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing 0bligations and Disclosure Requirements) Regulations,20L5, as amended ('the Listing Regulation') and has been initialed by us for identification purpose. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors in their meeting held on August 07, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, flnd AS 34) "lnterim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with regulation 33 of the Listing Regulations.0ur responsibility is to express a conclusion on the Statement based on our review. We conducted our review in accordance with the Standard on Review Engagements [SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" specified under section 143 (10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143 [10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ['lnd AS'] specified under Section 133 of the Companies Act,20L3 as amended, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of the Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement. The figures for the quarter ended March 3I, 2026 as reported in the Statement is the balancing figures between audited figures in respect of the full financial year ended on March 31,,2026 and the published year to date figures upto the end of the third quarter ended December 31.,2025. Also, the figures up to the end of the third quarter had only been reviewed by us as required under the Listing Regulations and not subjected to audit. Our conclusion on the Statement is not modified in respect of the [Showing first 8,000 characters — download PDF for full document]